Answers are grounded in this paper and cite their sources.
Monocentric study reveals respiratory MDRO colonization trends in lung transplant recipients, indicating urgent need for better infection control.
Background Infections by Multidrug-Resistant Organisms (MDROs) represent a critical hurdle in Lung Transplantation (LuTx). We aimed to estimate the incidence of respiratory MDRO colonization, identifying predictors and correlating colonization status with clinical infection. Methods Monocentric retrospective study in Siena University Hospital (2015–2025). Pre- and post-transplant clinical and colonization data, including donor-related, were collected. Early post-LuTx respiratory samples were recorded. Primary outcomes were prevalence of lung MDRO colonization post-LuTx and subsequent infection. Secondary outcomes included hospital mortality. Results Among 128 LuTx recipients (Table 1), 83 (64.8%) were males with a median age of 53.6 years (IQR 46–62). Indications for transplantation included 66 (51.6%) interstitial lung fibrosis patients and 19 (14.8) cystic fibrosis. 56 (43.8%) patients were hospitalized in the previous 2 years, 23 (18%) underwent LuTx during hospitalization and 16 (12.5%) were referred from other centers. Prior MDRO colonization in any site was documented in 16 (12.5%) patients, of which 10 (7.9%) non fermenting Gram negative bacteria DTR (NFGNB-DTR). Pre-operative support involved ECMO bridging in 14 (10.9%), intubation in 7 (5.3%), and tracheostomy in 6 (4.6%). Bilateral LuTx was performed in 96 (73.8%) cases. Prophylaxis regimens were standard (cefepime + vancomycin) in 111 (86.7%) and carbapenem-based in 10 (7.8%). Donor respiratory samples were positive in 45(34.6%) cases, yielding NFGNB-DTR in 17(13.1%). Over a median follow-up of 46 days [IQR 27–39], 34 (26.5%) patients acquired respiratory MDRO colonization post-LuTx, accounting for an incidence of 10.5 events per 100 person-weeks with a cumulative probability of 7.6% at 7 days rising to 45.3% at 30 days (Figure 1). Univariate and multivariate analysis (Table 2) identified carbapenem prophylaxis (HR 2.99, P= 0.027; aHR 3.69, P= 0.011) as significant predictor of respiratory colonization compared to standard prophylaxis. Tracheostomy beyond 15 days emerged as predictor on multivariate (aHR 2.53, P= 0.020). Any site infections occurred in 43 (33.1%) patients with a median onset of 15 days, of which 29 (67.4%) were caused by MDROs and 5 (3.9%) donor derived. Progression from colonization to infection was observed in 27(20.8%) patients. Overall, in-hospital mortality was 26(20%). Conclusions Our study confirms MDRO colonization as a major post-LuTx concern. Enhanced infection control measures, including pre-transplant, donor, and in-hospital management, are needed to reduce graft-related infections and MDRO in-hospital spreading.Figure 1.Cumulative Incidence of Colonization Over Time (Kaplan-Meier survival curve). Table 1.Population characteristics (n = 128)N (%) or median (IQR)Male gender83 (64.8%)Age, years53.6 [IQR 46–62]Caucasian123 (94.5%)Length of hospitalization post-LuTx, days46 [IQR 27–39]PRE TRANSPLANT PERIODReason for transplantation: Interstitial lung fibrosis66 (51.6%) COPD/bronchiectasias27 (21.1%) Cystic fibrosis19 (14.8%) Other16 (12.5%)Comorbidities Hypertension41 (32%) Heart disease35 (27.3%) Diabetes32 (25%) Peptic disease16 (12.5%) Liver disease16 (12.5%) Kidney disease3 (2.3%)Recent Hospitalization (last 3 months)36 (28.1%)Past colonization by MDRO16 (12.5%) NFGNB DTR10 (7.9%) ESBL2 (1.5%) CRE2 (1.5%)Multisite colonization by MDRO pre LuTx4 (3.3%)ECMO pre LuTx14 (10.9%)Orotracheal intubation pre LuTx7 (5.34%)Tracheostomy pre LuTx6 (4.6%)TRANSPLANTYear of LuTx2021 [2017–2023]Bilateral LuTx96 (73.8%)Antibiotic prophylaxis regimens: Standard (cefepime + vancomycin)111 (86.7%) Carbapenem + Glycopeptide10 (7.8%) Other7 (5.5%)DONOR CULTURESPositive respiratory tract samples45 (34.6%) Non fermentant DTR17 (13.1%) Enterobacterales ESBL10 (7.8%)POST TRANSPLANT PERIODCVC post LuTx (>15 days)94 (72.3%)Urinary catheter post LuTx (>15 days)72 (55.4%)CVVH post LuTx (>15 days)112 (86.2%)Tracheostomy post LuTx (>15 days)31 (23.8%)Orotracheal intubation post LuTx (>7 days)35 (26.9%)ECMO post LuTx (>48 h)23 (17.7%)INFECTION43 (33.1%) Time from LuTx (days)15 [5–23] Donor-derived infections5 (3.9%) MDRO29 (22.3%) Same agent Colonization → Infection27 (20.8%) LRTI35 (26.9%) Urinary tract infections4 (3.1%) CRBSI2 (1.5%) Outcome: exitus16 (14.6%)MDRO Multi Site Colonization post-LuTx14 (11%)Mechanical ventilation (days)12.8 [1–15]Intensive-care unit stay (days)17.2 [4–23]Death during hospitalization26 (20%)LuTx, Lung Transplant; COPD, Chronic Obstructive Pulmonary Disease; DTR, Difficult to treat resistance; ESBL, Extended-spectrum β-lactamases; CRE Carbapenem resistant Enterobactrales; ECMO pre LuTx Extracorporeal Membrane Oxygenation support while waiting for lung donor; CVC, Central venous Catheter; CVVH, Continuous Veno-Venous Hemofiltration; LRTI, low respiratory tract infection; CRBSI, Catheter-related bloodstream infection. Table 2.Predictors of time to LRT colonization by MDRO (Cox regression analysis, multivariate)HRPaHRPAntibiotic prophylaxis regimens: Anti Pseudo Cefalo + GlycopeptideRefRefRefRef Carba + Glycopeptide2.99 (1.13–7.91)0.0273.69 (1.35–10.0)0.011 Other0.52 (0.07–3.91)0.5320.31 (0.4–2.46)0.272Tracheostomy post LuTx (>15 days)1.81 (0.90–3.93)0.0932.53 (1.16–5.53)0.020
No takes yet. Share an insight, caveat, or question.
Lippi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: